These results suggest that MOAP-1 expression is down-regulated during breast cancer progression, may parallel the loss of RASSF1A, and subsequently contribute to the poor patient outcomes associated with more aggressive breast cancer subtypes. The gene discussed is MOAP1; the disease is breast carcinoma.